Home
Scholarly Works
The BNT162b2 (BioNTech/Pfizer) vaccine had 95%...
Journal article

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.

Abstract

SOURCE CITATION: Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-15. 33301246.

Authors

Chagla Z

Journal

Annals of Internal Medicine, Vol. 174, No. 2,

Publisher

American College of Physicians

Publication Date

February 1, 2021

DOI

10.7326/acpj202102160-015

ISSN

1056-8751

Contact the Experts team